LASAACI 2022 Fall Symposia

September 24, 2022

The Los Angeles Society of Allergy, Asthma and Clinical Immunology (LASAACI) is a CME educational meeting jointly provided by the American College of Allergy, Asthma and Immunology and the LASAACI.  The 2022 program is a four-hour event with speakers covering the topics of  EoE, AERD, MCAS.  The LASAACI Faculty are experts in their field and will provide evidence-based, clinical topics that address major aspects of attendee’s practices and will provide attendees exposure to new content.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Los Angeles Society of Allergy, Asthma and Clinical Immunology (LASAACI). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Commercial Support
None.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

  1.    Describe potential benefits and risks of JAK inhibitors in atopic dermatitis
  2.   Identify the key features for safe and successful implementation of OIT in the office-based setting 
  3.   Recognize the pathophysiology of airway epithelial inflammation
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Course opens: 
09/24/2022
Course expires: 
09/23/2023
Event starts: 
09/24/2022 - 8:30am CDT
Event ends: 
09/24/2022 - 1:30pm CDT
Add to calendar: 
Rating: 
0

Saturday, September 24, 2022

 

 

7:45AM-8:20AM             Registration, Exhibits & Coffee Break

 

8:20AM-8:30AM             WELCOME AND INTRODUCTION

Dean Chiang, MD, President/Program Director

Session Moderator: Dean Chiang, MD

 

8:30AM-9:30AM             Eosinophilic Esophagitis: Diagnosis, Treatment and Pathogenesis

Jonathan M. Spergel, MD, PhD

 

9:30AM-10:30AM          The American College of Allergy, Asthma & Immunology sponsored lecture:

Advocacy and Regulatory Update

James M. Tracy, DO

 

10:30AM-11:30AM        Buffet Brunch, Exhibits, Posters

 

11:30AM-12:30PM        AERD: From Diagnosis to Management in the Biologic Era

Katharine M. Woessner, MD, FAAAAI

 

12:30PM-1:30PM          Elevated Tryptase - now what?

Andrew A. White, MD, FAAAAI, FACAAI

 

1:30PM                           Adjourn

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company. The ACCME defines an “ineligible company” (formerly commercial interest) as a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers). For more information, visit www.accme.org. 
 
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
 
All identified relevant financial relationships have been mitigated.
Jonathan M. Spergel, MD, PhD - Speaker: Regeneron/Sanofi; Researcher: Regeneron/Sanofi|
Andrew A. White, MD, FAAAAI, FACAAI - Speaker: Blueprint
Katharine M. Woessner, MD, FAAAAI - Advisor: AstraZeneca, BioCryst, GSK; Speaker: AstraZeneca, GSK
Sonal Patel, MD - Speaker: Sanofi/Regeneron
Sheila M. Bonilla, MD - Researcher: GSK
Rita Kachru, MD - Researcher: Aimmune
Jonathan Corren, MD - Advisor: AstraZeneca, Regeneron, Sanofi; Independent Contractor: Novartis, Regeneron, Teva; Speaker: AstraZeneca, GSK, Novartis, Regeneron, Sanofi; Researcher: AstraZeneca

The following have no relevant financial relationships to disclose:
James M. Tracy, DO, FACAAI
Danica Schulte, MD
Dean Chiang, MD
Joseph Yusin, MD
Edward Hu, MD
Andrew K. Wong, MD
Karol Anderson

Available Credit

  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Please login or create an account to take this course.